Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Orchard Therapeutics Plc ADR (ORTX)

Orchard Therapeutics Plc ADR (ORTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 309,666
  • Shares Outstanding, K 125,371
  • Annual Sales, $ 2,600 K
  • Annual Income, $ -151,980 K
  • 60-Month Beta 1.12
  • Price/Sales 124.65
  • Price/Cash Flow N/A
  • Price/Book 1.37
Trade ORTX with:

Options Overview Details

View History
  • Implied Volatility 85.21%
  • Historical Volatility 80.13%
  • IV Percentile 26%
  • IV Rank 28.61%
  • IV High 212.38% on 09/29/20
  • IV Low 34.25% on 09/15/21
  • Put/Call Vol Ratio 1.24
  • Today's Volume 410
  • Volume Avg (30-Day) 158
  • Put/Call OI Ratio 0.14
  • Today's Open Interest 2,453
  • Open Int (30-Day) 2,066

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/21
See More
  • Average Estimate -0.27
  • Number of Estimates 5
  • High Estimate -0.20
  • Low Estimate -0.31
  • Prior Year -0.20
  • Growth Rate Est. (year over year) -35.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.38 +3.78%
on 09/22/21
3.18 -22.33%
on 09/02/21
-0.33 (-11.79%)
since 08/24/21
3-Month
2.32 +6.47%
on 08/20/21
5.02 -50.80%
on 06/28/21
-2.38 (-49.07%)
since 06/24/21
52-Week
2.32 +6.47%
on 08/20/21
9.08 -72.80%
on 02/12/21
-2.10 (-45.95%)
since 09/24/20

Most Recent Stories

More News
Orchard Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Business Updates

Regulatory feedback obtained on OTL-200 (MLD) and OTL-203 (MPS-IH) programs

ORTX : 2.47 (-4.26%)
Orchard Therapeutics and Pharming Group Announce Collaboration to Develop and Commercialize ex vivo autologous HSC Gene Therapy for Hereditary Angioedema

Highlights the broader potential of Orchard's ex vivo HSC gene therapy platform approach in new and larger indications

ORTX : 2.47 (-4.26%)
Orchard Therapeutics Announces Regulatory and Clinical Updates for Lead Gene Therapy Programs

Expected clinical package for OTL-200 BLA for MLD using data from existing patients clarified with FDA

ORTX : 2.47 (-4.26%)
Orchard Therapeutics Reports First Quarter 2021 Financial Results and Provides Recent Business Updates

Commercial Activities Advancing for Upcoming Launch of Libmeldy (atidarsagene autotemcel) for Eligible Patients with Early-onset MLD in Germany

ORTX : 2.47 (-4.26%)
Orchard Therapeutics Announces New England Journal of Medicine Publication of HSC Gene Therapy Data for ADA-SCID

100% overall survival and greater-than or equal to95% event-free survival observed at two and three years following one-time treatment with lentiviral HSC gene therapy

ORTX : 2.47 (-4.26%)
Orchard Therapeutics Announces Multiple Presentations at the 24th Annual Meeting of the American Society of Gene & Cell Therapy

Seven abstracts accepted show the potential of HSC gene therapy to transform the treatment of multiple severe rare disorders

ORTX : 2.47 (-4.26%)
Thinking about buying stock in Orchard Therapeutics, Salarius Pharmaceuticals, Seelos Therapeutics, Evolus, or ENDRA Life Sciences?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ORTX, SLRX, SEEL, EOLS, and NDRA.

EOLS : 7.87 (-2.72%)
ORTX : 2.47 (-4.26%)
SEEL : 2.09 (-4.57%)
SLRX : 1.1500 (+3.60%)
NDRA : 1.8000 (-0.55%)
First Week of November 19th Options Trading For Orchard Therapeutics (ORTX)

Investors in Orchard Therapeutics plc saw new options become available this week, for the November 19th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is...

ORTX : 2.47 (-4.26%)
Health Logic Interactive Inc. Announces the Appointment of Dr. Marta New, MBA to the Advisory Board

Health Logic Interactive Inc. Announces the Appointment of Dr. Marta New, MBA to the Advisory Board

ORTX : 2.47 (-4.26%)
Thinking about buying stock in OpGen, XpresSpa, Jaguar Health, Orchard Therapeutics, or Novan?

, /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for OPGN, XSPA, JAGX, ORTX, and NOVN.

NOVN : 8.14 (-3.78%)
ORTX : 2.47 (-4.26%)
XSPA : 1.6000 (-1.23%)
JAGX : 2.24 (-8.20%)
OPGN : 3.05 (-1.93%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Orchard Therapeutics plc is a biopharmaceutical company. It offers medical research, gene therapy and inherited disorder treatment services which transforms the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. Orchard Therapeutics plc is based...

See More

Key Turning Points

3rd Resistance Point 2.60
2nd Resistance Point 2.56
1st Resistance Point 2.52
Last Price 2.47
1st Support Level 2.44
2nd Support Level 2.40
3rd Support Level 2.36

See More

52-Week High 9.08
Fibonacci 61.8% 6.50
Fibonacci 50% 5.70
Fibonacci 38.2% 4.90
Last Price 2.47
52-Week Low 2.32

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar